
TY  - JOUR
A1  - Singh, Kasha P 
A1  - Sasadeusz, Joe 
A1  - Lewin, Sharon R 
A1  - Audsley, Jennifer 
T1  - <i>Corrigendum to</i>: Therapeutics for COVID-19: established and in development
JF  - Microbiology Australia
JO  - Microbiol. Aust.
Y1  - 2021
VL  - 42
IS  - 1
SP  - 46
EP  - 46
KW  - 
UR  - https://doi.org/10.1071/MA20058_CO 
N2  - COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first recognised in late 2019, with over 30&#x2009;000&#x2009;000 cases and over 1&#x2009;000&#x2009;000 deaths reported by the end of September 2020. SARS-CoV-2 infection is usually associated with fever, cough, coryza, dyspnoea, anosmia, headache and fatigue and may cause pneumonia and hypoxemia. An excessive/dysregulated inflammatory response may lead to lung damage including acute respiratory distress syndrome (ARDS), coagulopathy and other complications. Mortality amongst hospitalised patients is higher in those needing intensive care. In Australia over 27&#x2009;000 cases with 882 deaths had been reported by 30 September, most in Victoria. Two therapies have proven beneficial in treatment of hospitalised patients in expedited randomised placebo-controlled trials and are now in widespread use. Dexamethasone improved survival of those requiring respiratory support and the antiviral agent remdesivir decreased time to recovery in mild-moderate disease. Remdesivir was authorised by the Australian Therapeutic Goods Administration in July 2020. Over 200 other therapeutics are being tested for COVID-19 in more than 2000 clinical trials, and many more agents are in preclinical development. We review the evidence for some of the candidates for therapy in COVID-19. 
ER  -

